2.70
+0.27(+11.11%)
Currency In USD
| Previous Close | 2.43 |
| Open | 2.59 |
| Day High | 2.78 |
| Day Low | 2.57 |
| 52-Week High | 8.94 |
| 52-Week Low | 1.79 |
| Volume | 865,239 |
| Average Volume | 386,732 |
| Market Cap | 57.93M |
| PE | -2.06 |
| EPS | -1.31 |
| Moving Average 50 Days | 2.32 |
| Moving Average 200 Days | 3.14 |
| Change | 0.27 |
Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)
Newsfile
Sep 24, 2025 1:26 PM GMT
Dallas, Texas--(Newsfile Corp. - September 24, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX): Stonegate Capital Partners initiates their coverage on Medicus Pharma Ltd. (NASDAQ: MDCX). Medicus advanced several strategic initiatives in 2Q2
Medicus Pharma Ltd. Completes Acquisition of Antev Limited
Newsfile
Sep 02, 2025 11:30 AM GMT
Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunityPatrick J. M
Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights
Newsfile
Aug 21, 2025 11:30 AM GMT
US Food and Drug Administration (FDA) has accepted the company's Type C meeting request and SKNJCT-003 Phase 2 study has randomized more than 75% of patientsPhiladelphia, Pennsylvania--(Newsfile Corp. - August 21, 2025) - Medicus Pharma Ltd. (NASDAQ: